Eaton Corp PLC

Shareholders are asked to reappoint Ernst & Young LLP as Eaton's independent auditor for the 2026 fiscal year and to authorize the Audit Committee to set the auditor’s remuneration. Management and the Audit Committee recommend reappointment based on Ernst & Young’s long tenure (auditor since 1923), deep knowledge of Eaton’s operations and industries, and perceived benefits for continuity and audit quality. The proposal is routine and standard: reappointing the incumbent auditor preserves audit continuity and leverages institutional knowledge about the company’s financial reporting and internal controls. The Audit Committee emphasizes that it has sole authority to appoint and compensate the auditor, reviews auditor independence and pre-approves non-audit services, and has concluded the scope and fees are appropriate. A representative of Ernst & Young will attend the meeting and be available to respond to shareholder questions. The Board’s recommendation points to audit firm expertise and longstanding relationship as the primary rationale; potential governance considerations for investors include auditor tenure, periodic firm rotation considerations, and the Audit Committee’s oversight of independence and non-audit services.

This management proposal requests an advisory 'say-on-pay' approval of the Company's executive compensation as disclosed in the Proxy Statement, including the Compensation Discussion and Analysis and compensation tables. Although non-binding, the board and Compensation and Organization Committee view the vote as important feedback and will consider the results in future compensation decisions — the company previously received 93.2% support in 2025. The compensation program emphasizes pay-for-performance with approximately 80% of NEO pay at-target being performance-based, uses Adjusted EPS and Adjusted OCF for short-term incentives, and a TSR-based ESIP for long-term incentives. Management’s justification focuses on alignment with shareholder value, rigorous metrics, clawback policy, share ownership requirements, and other governance practices. Investors should weigh the strong historical shareholder support alongside the program’s design (relative TSR PSUs, time-based RSUs and options, caps, and clawback) and consider how well realized pay tracked multi-year performance, material governance features, and any potential pay-related risks.

Proposal 4 seeks shareholder approval under Irish law to grant the Board authority to issue up to an aggregate nominal amount equal to approximately 20% of the company's issued share capital for an 18-month period. Management frames this as routine and customary for Irish-listed companies and not as an increase in authorized share capital, but as enabling the Board to act flexibly to issue already-authorized shares for general corporate purposes including acquisitions and capital raising. The request reflects standard market practice; investors should consider potential dilutive impact, the contemporaneous share repurchase program which can offset dilution, and safeguards such as the finite 18-month term and the Board’s fiduciary duty. The Board recommends approval because it provides necessary flexibility in capital management while remaining within market norms.

Proposal 5 requests a special resolution to permit the Board, subject to passing Proposal 4, to disapply statutory pre-emption rights—i.e., to allot equity securities for cash without a pro-rata offer to existing shareholders—in specified circumstances limited to rights issues and otherwise up to approximately 20% of issued share capital for 18 months. Management argues this is customary in Ireland and necessary to permit efficient capital raising and strategic transactions without procedural delay. Investors should weigh the standard market rationale against dilution risk; the proposal includes constraints (20% cap, 18-month term, and requirement of a 75% shareholder approval) that mitigate abuse while aligning Eaton with common practices for NYSE-listed Irish companies.

This proposal requests an ordinary resolution authorizing the Company and its subsidiaries to repurchase up to approximately 10% of the Company’s outstanding shares in the open market over an 18-month period with specified price collars (70%–120% of prior day’s NYSE closing price). Management frames this as a standard capital allocation tool to return value to shareholders and manage dilution, noting historical repurchases and that the authority would allow subsidiaries to participate in repurchases under Irish law. Investors evaluating the proposal should consider the potential for efficient capital deployment and EPS accretion versus alternative uses of capital, and the existence of guardrails (share cap, price limits, and time limit) which reduce the risk of opportunistic repurchases.